New antileishmanial candidates and lead compounds

  • Richard J
  • Werbovetz K
  • 62


    Mendeley users who have this article in their library.
  • 41


    Citations of this article.


Although miltefosine and paromomycin were registered as clinical agents against visceral leishmaniasis in the last decade, the antileishmanial drug arsenal still requires improvement, particularly in the area of oral antileishmanial drugs for both visceral and cutaneous diseases. Several new compounds and formulations have displayed promising efficacy in animal models of leishmaniasis, including the 8-aminoquinoline NPC1161, a series of bis-quinolines, DB766, rhodacyanine dyes, amiodarone, and an oral formulation of amphotericin B. Herein we provide a review of those molecules whose antileishmanial properties have been described over the past few years and a brief assessment of the studies required to identify new preclinical antileishmanial candidates. © 2010 Elsevier Ltd.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Julian V. Richard

  • Karl A. Werbovetz

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free